In oncology, we are trained to think in numbers. Overall survival. Progression-free survival. Hazard ratios. Response rates. Kaplan–Meier curves.
These metrics are indispensable. They allow us to compare treatments, interpret clinical trials, and advance cancer care with scientific rigor. Yet they do not fully capture what patients are actually asking when they ask whether a treatment is“worth it.”
Because patients do not experience survival as a statistical construct. They experience it as daily life.
They experience it in whether they can climb the stairs without needing to stop halfway. In whether they can think clearly enough to follow a conversation, read a page, or remember why they walked into a room. In whether nausea, fatigue, pain, or emotional burden gradually take over the structure of an ordinary day.
For many patients, the central question is not simply, “How long will I live?” It is, “What will that life feel like?”
That distinction matters more than oncology has historically acknowledged.
Why Traditional Endpoints Are Not Enough
Modern cancer care has been built around endpoints that are measurable, reproducible, and acceptable to regulators. Overall survival remains the gold standard. Progression-free survival, disease-free survival, and radiographic response are also central to how we evaluate benefit.
But these endpoints are imperfect proxies for lived experience.
A scan may improve while cognition worsens.
A tumor may shrink while fatigue becomes overwhelming.
A progression-free interval may lengthen while autonomy quietly narrows.
This is not an argument against survival endpoints. It is an argument against treating them as complete. The difference between biological control and meaningful living is where much of oncology’s most important work still remains.
Patients Define Benefit Differently
Clinicians often define success through disease control. Patients often define it through function, identity, and continuity of self.
They may measure improvement in being able to return to work, go out with friends, cook for their family, or simply remain mentally present in their daily life. They may value fewer hospital visits, less nausea, preserved speech, intact mobility, or the ability to feel like themselves for longer.
This is precisely why patient-reported outcomes (PROs) matter.
PROs are structured reports coming directly from patients about symptoms, functioning, and health-related quality of life (HRQoL), without clinician interpretation. They represent a shift from observing disease to understanding lived experience.
And increasingly, they are not optional.
The Evidence Is Now Too Strong to Ignore
The argument for integrating patient-reported outcomes is no longer philosophical.
A recent large systematic review and meta-analysis including over 44,000 patients across 69 randomized clinical trials demonstrated that PROs carry independent prognostic value for overall survival. Better global health status and quality-of-life scores were associated with improved survival, while higher symptom burden—such as fatigue, pain, and nausea—was associated with worse outcomes.
This is a critical shift.
Symptoms and quality of life are not just consequences of treatment. They may also be predictors of survival.
Interventional data support this concept.
In a landmark randomized trial by Basch et al., electronic patient-reported symptom monitoring during routine chemotherapy significantly improved overall survival (31.2 months vs 26.0 months), while also reducing emergency visits and preserving quality of life.
Similarly, Denis et al. demonstrated that web-based follow-up using patient-reported symptoms in lung cancer patients improved overall survival (19 months vs 12 months), likely by enabling earlier detection of relapse and maintaining performance status.
These findings suggest something profound:
Listening to patients in a structured, systematic way may not only improve how they feel—it may help them live longer.
The Gap Between What We Record and What Patients Live
One of the persistent challenges in oncology is the discrepancy between clinician- reported toxicity and patient-experienced symptoms.
Fatigue, dyspnea, pain, insomnia, and cognitive impairment are often underestimated when assessed solely through clinician grading systems. What appears “manageable” in a chart may feel life-altering to a patient.
This gap has consequences.
What looks acceptable in a trial may translate into a life with reduced autonomy, impaired cognition, or persistent discomfort. Without direct patient input, these dimensions risk being under-recognized and undertreated.
This is why the question “Did the treatment work?” is often too narrow. A more meaningful question is: Did the treatment prolong life in a way the patient could still recognize as living?
Oncology Is Evolving—But Not Fast Enough
The field is beginning to respond.
The SISAQOL-IMI initiative has developed international consensus guidelines for integrating patient-reported outcomes into cancer clinical trials, emphasizing standardized design, analysis, and reporting.
The EORTC Quality of Life Group has advanced more flexible and adaptive measurement strategies, aiming to better capture patient experience across different diseases and treatment settings.
These are important steps.
But the integration of PROs into daily clinical decision-making remains inconsistent. Too often, quality of life is still treated as a secondary endpoint rather than a co- primary dimension of care.
What Truly Patient-Centered Oncology Should Mean
Patient-centered oncology is often discussed in terms of communication and empathy. But it is also about redefining benefit.
It means acknowledging that survival alone is not always the outcome that matters most. It means integrating function, symptom burden, cognition, and dignity into how we define treatment success. It means understanding that when patients ask about prognosis, they are often asking not only about time—but about identity.
Will I still be able to think clearly?
Will I still be able to live independently?
Will I still feel like myself?
These are not secondary concerns. They are central to what survival actually means.
Patients do not measure survival the way clinicians do.
We measure months gained, curves separated, and risk reduced. Patients measure mornings without nausea, conversations they can follow, and days in which they still feel present in their own lives.
Both perspectives matter.
But if oncology is to become truly patient-centered, it cannot stop at proving that a treatment extends life. It must also ask what that life looks like while it is being extended. Because the most meaningful endpoint is not survival alone.
It is survival that still feels like living.
Written By Eftychia Tataridou, MD